Patent application number | Description | Published |
20090246196 | COMBINED TARGETED THERAPY FOR THE TREATMENT OF PROLIFERATIVE DISEASE - A method of treating an individual comprising: evaluating the disease state of said individual through quantitative and/or qualitative assays; administering in amounts sufficient to treat said disease at least three agents wherein at least one agent is an inhibitor of the human epidermal receptor pathway, at least one agent is signal transduction inhibitor and at least one agent is an angiogenesis inhibitor and; reevaluating the disease state of said individual presenting through quantitative and/or qualitative assays. A composition comprising a first agent that is an inhibitor of the human epidermal receptor pathway, a second agent that is an angiogenesis inhibitor and a third agent that is an inhibitor of Akt wherein said first agent, second agent, third agent and combinations thereof are present in amounts that when administered to an individual in a diseased state are sufficient to treat said disease. | 10-01-2009 |
20110027373 | METHODS AND COMPOSITIONS FOR MODULATING SIALIC ACID PRODUCTION AND TREATING HEREDITARY INCLUSION BODY MYOPATHY - According to certain embodiments of the present invention, methods for modulating the production of sialic acid in a system are provided, which comprise providing the system with a wild-type GNE-encoding nucleic acid sequence. According to such embodiments, the system may comprise a cell, muscular tissue, or other desirable targets. Similarly, the present invention encompasses methods for producing wild-type GNE in a system that comprises a mutated endogenous GNE-encoding sequence. In other words, the present invention includes providing, for example, a cell or muscular tissue that harbors a mutated (defective) GNE-encoding sequence with a functional wild-type GNE encoding sequence. | 02-03-2011 |
20110117183 | Novel Therapeutic RNA Interference Technology Targeted to the PDX-1 Oncogene in PDX-1 Expressing Neuroendocrine Tumors - A bifunctional shRNA-based composition and methods for knocking down the expression of the PDX-1 oncogene in target cells is described herein. The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues overexpressing the PDX-1 oncogene. | 05-19-2011 |
20110150832 | FURIN-KNOCKDOWN BI-FUNCTIONAL RNA - Compositions and methods to attenuate the immunosuppressive activity of TGF-β through the use of bi-functional shRNAs is described herein. The bi-functional shRNAs of the present invention knocks down the expression of furin in cancer cells to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene. | 06-23-2011 |
20110262408 | FURIN-KNOCKDOWN AND GM-CSF-AUGMENTED (FANG) CANCER VACCINE - Compositions and methods for cancer treatment are discloses herein. More specifically the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-β through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene. | 10-27-2011 |
20110286979 | CHEMOSENSITIZATION BY BI-FUNCTIONAL SMALL HAIRPIN RNA (bi-shRNA) - Compositions and methods of augmenting the anti-tumor activities of docetaxel and other taxanes by combination with a bi-functional small hairpin RNA (bi-shRNA) is described herein. The instant invention describes the interactive outcome of STMN1 knockdown with docetaxel. In vitro docetaxel (DOC) dose response assessments with or without co-treatment with bi-shRNA | 11-24-2011 |
20120251617 | BI-FUNCTIONAL SHRNA TARGETING STATHMIN 1 AND USES THEREOF - The present invention includes bifunctional shRNAs capable of reducing an expression of a Stathmin 1 gene; wherein at least one target site sequence of the bifunctional RNA molecule is located within the Stathmin 1 gene, wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of Stathmin 1. | 10-04-2012 |
20130064881 | COMPOSITIONS AND METHODS FOR TREATING PROSTATE CANCER - Compositions and methods to interfere with Androgen Receptor (AR) action based on bifunctional shRNA, targeting the AR and/or expression of SRC derived peptides are disclosed herein. | 03-14-2013 |
20130078279 | FURIN-KNOCKDOWN AND GM-CSF-AUGMENTED (FANG) CANCER VACCINE - Compositions and methods for cancer treatment are discloses herein. More specifically the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-β through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene. | 03-28-2013 |
20130084331 | Novel Therapeutic RNA Interference Technology Targeted to the PDX-1 Oncogene in PDX-1 Expressing Neuroendocrine Tumors - A bifunctional shRNA-based composition and methods for knocking down the expression of the PDX-1 oncogene in target cells is described herein. The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues overexpressing the PDX-1 oncogene. | 04-04-2013 |
20130259925 | METHODS AND COMPOSITIONS TO TREAT CANCER USING BIFUNCTIONAL SRC 3 shRNA - The present invention includes compositions and methods of making and using an expression vector comprising a promoter and a nucleic acid insert operably linked to the promoter, wherein the insert encodes one or more short hairpin RNAs (shRNA) capable of inhibiting an expression of a SRC-3 gene via RNA interference, wherein the one or more shRNA comprise a bifunctional RNA molecule that activates a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of the SRC-3. | 10-03-2013 |
20130259926 | BI-FUNCTIONAL shRNA TARGETING MESOTHELIN AND USES THEREOF - The present invention includes bifunctional shRNAs capable of reducing an expression of a Mesothelin gene; wherein at least one target site sequence of the bifunctional RNA molecule is located within the Mesothelin, wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of Mesothelin. | 10-03-2013 |
20130259927 | Ewing's Sarcoma Bifunctional shRNA Design - The present invention includes compositions and methods of making and using an imaging label comprising an expression vector comprising a promoter; and a nucleic acid insert operably linked to the promoter, wherein the insert encodes one or more short hairpin RNAs (shRNA) capable of inhibiting an expression of a target gene sequence that is a EWS-FLI1 fusion gene, a EWSR1-ERG fusion gene, or both in Ewing's sarcoma via RNA interference; wherein the one or more shRNA comprise a bifunctional RNA molecule that activates a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of the target gene. | 10-03-2013 |
20130266639 | METHODS FOR TREATING TRIPLE NEGATIVE BREAST CANCER USING BIFUNCTIONAL SRC 3 shRNA - The present invention includes compositions and methods treating triple negative breast cancer comprising administering a therapeutically effective amount of a formulation that includes vector that expresses an SRC-1-specific bifunctional shRNA, an SRC-3-specific bifunctional shRNA, or both, to impair triple negative breast cancer cell growth. | 10-10-2013 |
20130295160 | ANTAGONISTS OF MIR-196A - A miR-196a antagonist capable of inhibiting a miR-196a activity, the miR-196a antagonist comprising one or more target sites for miR-196a. Included is also an expression vector comprising a promoter and a nucleic acid insert operably linked to the promoter, wherein the insert encodes one or more miR-196a antagonists capable of inhibiting a miR-196a activity. In one example, the one or more miR-196a antagonists comprise at least one stem-loop structure comprising a guide strand that comprises a sequence that is complementary to miR-196a, the stem-loop structure further comprising a passenger strand that comprises a mismatch. | 11-07-2013 |
20130302407 | Bi-Functional Short-Hairpin RNA (Bi-shRNA) Specific for Single-Nucleotide KRAS Mutations - The present invention includes compositions and methods for making and using a bifunctional shRNAs capable of reducing an expression of a K-ras gene, e.g., a mutated K-ras gene, wherein at least one target site sequence of the bifunctional RNA molecule is located within the K-ras gene and wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of K-ras. | 11-14-2013 |
20140134236 | INDIVIDUALIZED CANCER THERAPY - In certain preferred embodiments, the invention provides methods for treating cancer, which comprise (a) obtaining a specimen of cancer tissue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue from such patient; (c) extracting total protein and RNA from the cancer tissue and normal tissue; (d) obtaining a protein expression profile of the cancer tissue and normal tissue using 2D DIGE and mass spectrometry; (e) identifying proteins that are expressed in such cancer tissue at significantly different levels than in the normal tissue; (f) obtaining a gene expression profile of the cancer tissue and normal tissue using microarray technology and comparing the results thereof to the protein expression profile; (g) prioritizing over-expressed proteins by assessing the connectivity thereof to other cancer-related or stimulatory proteins; (h) designing an appropriate RNA interference expression cassette to, directly or indirectly, modulate the expression of genes encoding such prioritized proteins; (i) incorporating said cassette into an appropriate delivery vehicle; and (j) providing the patient with an effective amount of the delivery vehicle to, directly or indirectly, modify the expression (i.e., production) of such proteins. | 05-15-2014 |